Search

Your search keyword '"Sullivan, Daniel M."' showing total 465 results
Start Over Author "Sullivan, Daniel M."
465 results on '"Sullivan, Daniel M."'

1. Company L (the Kosovo commitment)

Author

Sullivan, Daniel M., Capt

Subjects
OPERATION - Joint Guardian - Lessons Learned, PEACEKEEPING - Serbia and Montenegro - Lessons Learned, URBAN WARFARE - Lessons Learned
Published
1999

2. Spending and Job-Finding Impacts of Expanded Unemployment Benefits: Evidence from Administrative Micro Data.

Author

Ganong, Peter, Greig, Fiona, Noel, Pascal, Sullivan, Daniel M., and Vavra, Joseph

Abstract

We show that the largest increase in unemployment benefits in US history had large spending impacts and small job-finding impacts. This finding has three implications. First, increased benefits were important for explaining aggregate spending dynamics—but not employment dynamics—during the pandemic. Second, benefit expansions allow us to study the MPC of normally low-liquidity households in a high-liquidity state. These households still have high MPCs. This suggests a role for permanent behavioral characteristics, rather than just current liquidity, in driving spending behavior. Third, the mechanisms driving our results imply that temporary benefit supplements are a promising countercyclical tool. (JEL E21, E24, E32, E62, E71, G51, J65) [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

7. Data from Phase I Clinical Trial of Selinexor in Combination with Daunorubicin and Cytarabine in Previously Untreated Poor-Risk Acute Myeloid Leukemia

Author

Sweet, Kendra, primary, Komrokji, Rami, primary, Padron, Eric, primary, Cubitt, Christopher L., primary, Turner, Joel G., primary, Zhou, Junmin, primary, List, Alan F., primary, Sallman, David A., primary, Dawson, Jana L., primary, Sullivan, Daniel M., primary, Chavez, Julio, primary, Shah, Bijal D., primary, and Lancet, Jeffrey E., primary

Published
2023
Full Text
View/download PDF

8. Supplementary Expression Data from Randomized Trial of Oral Cyclophosphamide and Veliparib in High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers, or BRCA-Mutant Ovarian Cancer

Author

Kummar, Shivaani, primary, Oza, Amit M., primary, Fleming, Gini F., primary, Sullivan, Daniel M., primary, Gandara, David R., primary, Naughton, Michael J., primary, Villalona-Calero, Miguel A., primary, Morgan, Robert J., primary, Szabo, Peter M., primary, Youn, Ahrim, primary, Chen, Alice P., primary, Ji, Jiuping, primary, Allen, Deborah E., primary, Lih, Chih-Jian, primary, Mehaffey, Michele G., primary, Walsh, William D., primary, McGregor, Paul M., primary, Steinberg, Seth M., primary, Williams, P. Mickey, primary, Kinders, Robert J., primary, Conley, Barbara A., primary, Simon, Richard M., primary, and Doroshow, James H., primary

Published
2023
Full Text
View/download PDF

9. Figure S3 from Randomized Trial of Oral Cyclophosphamide and Veliparib in High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers, or BRCA-Mutant Ovarian Cancer

Author

Kummar, Shivaani, primary, Oza, Amit M., primary, Fleming, Gini F., primary, Sullivan, Daniel M., primary, Gandara, David R., primary, Naughton, Michael J., primary, Villalona-Calero, Miguel A., primary, Morgan, Robert J., primary, Szabo, Peter M., primary, Youn, Ahrim, primary, Chen, Alice P., primary, Ji, Jiuping, primary, Allen, Deborah E., primary, Lih, Chih-Jian, primary, Mehaffey, Michele G., primary, Walsh, William D., primary, McGregor, Paul M., primary, Steinberg, Seth M., primary, Williams, P. Mickey, primary, Kinders, Robert J., primary, Conley, Barbara A., primary, Simon, Richard M., primary, and Doroshow, James H., primary

Published
2023
Full Text
View/download PDF

10. Supplementary Methods, Tables S1 and S2, Figure Legend from Randomized Trial of Oral Cyclophosphamide and Veliparib in High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers, or BRCA-Mutant Ovarian Cancer

Author

Kummar, Shivaani, primary, Oza, Amit M., primary, Fleming, Gini F., primary, Sullivan, Daniel M., primary, Gandara, David R., primary, Naughton, Michael J., primary, Villalona-Calero, Miguel A., primary, Morgan, Robert J., primary, Szabo, Peter M., primary, Youn, Ahrim, primary, Chen, Alice P., primary, Ji, Jiuping, primary, Allen, Deborah E., primary, Lih, Chih-Jian, primary, Mehaffey, Michele G., primary, Walsh, William D., primary, McGregor, Paul M., primary, Steinberg, Seth M., primary, Williams, P. Mickey, primary, Kinders, Robert J., primary, Conley, Barbara A., primary, Simon, Richard M., primary, and Doroshow, James H., primary

Published
2023
Full Text
View/download PDF

11. Sup Figure 3 from Interrogating Two Schedules of the AKT Inhibitor MK-2206 in Patients with Advanced Solid Tumors Incorporating Novel Pharmacodynamic and Functional Imaging Biomarkers

Author

Yap, Timothy A., primary, Yan, Li, primary, Patnaik, Amita, primary, Tunariu, Nina, primary, Biondo, Andrea, primary, Fearen, Ivy, primary, Papadopoulos, Kyriakos P., primary, Olmos, David, primary, Baird, Richard, primary, Delgado, Liliana, primary, Tetteh, Ernestina, primary, Beckman, Robert A., primary, Lupinacci, Lisa, primary, Riisnaes, Ruth, primary, Decordova, Shaun, primary, Heaton, Simon P., primary, Swales, Karen, primary, deSouza, Nandita M., primary, Leach, Martin O., primary, Garrett, Michelle D., primary, Sullivan, Daniel M., primary, de Bono, Johann S., primary, and Tolcher, Anthony W., primary

Published
2023
Full Text
View/download PDF

12. Sup Figure 4 from Interrogating Two Schedules of the AKT Inhibitor MK-2206 in Patients with Advanced Solid Tumors Incorporating Novel Pharmacodynamic and Functional Imaging Biomarkers

Author

Yap, Timothy A., primary, Yan, Li, primary, Patnaik, Amita, primary, Tunariu, Nina, primary, Biondo, Andrea, primary, Fearen, Ivy, primary, Papadopoulos, Kyriakos P., primary, Olmos, David, primary, Baird, Richard, primary, Delgado, Liliana, primary, Tetteh, Ernestina, primary, Beckman, Robert A., primary, Lupinacci, Lisa, primary, Riisnaes, Ruth, primary, Decordova, Shaun, primary, Heaton, Simon P., primary, Swales, Karen, primary, deSouza, Nandita M., primary, Leach, Martin O., primary, Garrett, Michelle D., primary, Sullivan, Daniel M., primary, de Bono, Johann S., primary, and Tolcher, Anthony W., primary

Published
2023
Full Text
View/download PDF

13. Sup Figure 1 from Interrogating Two Schedules of the AKT Inhibitor MK-2206 in Patients with Advanced Solid Tumors Incorporating Novel Pharmacodynamic and Functional Imaging Biomarkers

Author

Yap, Timothy A., primary, Yan, Li, primary, Patnaik, Amita, primary, Tunariu, Nina, primary, Biondo, Andrea, primary, Fearen, Ivy, primary, Papadopoulos, Kyriakos P., primary, Olmos, David, primary, Baird, Richard, primary, Delgado, Liliana, primary, Tetteh, Ernestina, primary, Beckman, Robert A., primary, Lupinacci, Lisa, primary, Riisnaes, Ruth, primary, Decordova, Shaun, primary, Heaton, Simon P., primary, Swales, Karen, primary, deSouza, Nandita M., primary, Leach, Martin O., primary, Garrett, Michelle D., primary, Sullivan, Daniel M., primary, de Bono, Johann S., primary, and Tolcher, Anthony W., primary

Published
2023
Full Text
View/download PDF

14. Supplementary Data from Phase I Clinical Trial of Selinexor in Combination with Daunorubicin and Cytarabine in Previously Untreated Poor-Risk Acute Myeloid Leukemia

Author

Sweet, Kendra, primary, Komrokji, Rami, primary, Padron, Eric, primary, Cubitt, Christopher L., primary, Turner, Joel G., primary, Zhou, Junmin, primary, List, Alan F., primary, Sallman, David A., primary, Dawson, Jana L., primary, Sullivan, Daniel M., primary, Chavez, Julio, primary, Shah, Bijal D., primary, and Lancet, Jeffrey E., primary

Published
2023
Full Text
View/download PDF

16. Supplementary Data from Potentiation of a Topoisomerase I Inhibitor, Karenitecin, by the Histone Deacetylase Inhibitor Valproic Acid in Melanoma: Translational and Phase I/II Clinical Trial

Author

Daud, Adil I., primary, Dawson, Jana, primary, DeConti, Ronald C., primary, Bicaku, Elona, primary, Marchion, Douglas, primary, Bastien, Sem, primary, Hausheer, Frederick A., primary, Lush, Richard, primary, Neuger, Anthony, primary, Sullivan, Daniel M., primary, and Munster, Pamela N., primary

Published
2023
Full Text
View/download PDF

17. Data from Randomized Trial of Oral Cyclophosphamide and Veliparib in High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers, or BRCA-Mutant Ovarian Cancer

Author

Kummar, Shivaani, primary, Oza, Amit M., primary, Fleming, Gini F., primary, Sullivan, Daniel M., primary, Gandara, David R., primary, Naughton, Michael J., primary, Villalona-Calero, Miguel A., primary, Morgan, Robert J., primary, Szabo, Peter M., primary, Youn, Ahrim, primary, Chen, Alice P., primary, Ji, Jiuping, primary, Allen, Deborah E., primary, Lih, Chih-Jian, primary, Mehaffey, Michele G., primary, Walsh, William D., primary, McGregor, Paul M., primary, Steinberg, Seth M., primary, Williams, P. Mickey, primary, Kinders, Robert J., primary, Conley, Barbara A., primary, Simon, Richard M., primary, and Doroshow, James H., primary

Published
2023
Full Text
View/download PDF

19. Sup Figure 2 from Interrogating Two Schedules of the AKT Inhibitor MK-2206 in Patients with Advanced Solid Tumors Incorporating Novel Pharmacodynamic and Functional Imaging Biomarkers

Author

Yap, Timothy A., primary, Yan, Li, primary, Patnaik, Amita, primary, Tunariu, Nina, primary, Biondo, Andrea, primary, Fearen, Ivy, primary, Papadopoulos, Kyriakos P., primary, Olmos, David, primary, Baird, Richard, primary, Delgado, Liliana, primary, Tetteh, Ernestina, primary, Beckman, Robert A., primary, Lupinacci, Lisa, primary, Riisnaes, Ruth, primary, Decordova, Shaun, primary, Heaton, Simon P., primary, Swales, Karen, primary, deSouza, Nandita M., primary, Leach, Martin O., primary, Garrett, Michelle D., primary, Sullivan, Daniel M., primary, de Bono, Johann S., primary, and Tolcher, Anthony W., primary

Published
2023
Full Text
View/download PDF

20. Supplementary Data from Phase I Trial of Bortezomib (PS-341; NSC 681239) and Alvocidib (Flavopiridol; NSC 649890) in Patients with Recurrent or Refractory B-Cell Neoplasms

Author

Holkova, Beata, primary, Perkins, E. Brent, primary, Ramakrishnan, Viswanathan, primary, Tombes, Mary Beth, primary, Shrader, Ellen, primary, Talreja, Neha, primary, Wellons, Martha D., primary, Hogan, Kevin T., primary, Roodman, G. David, primary, Coppola, Domenico, primary, Kang, Loveleen, primary, Dawson, Jana, primary, Stuart, Robert K., primary, Peer, Cody, primary, Figg, William D., primary, Kolla, Sarah, primary, Doyle, Austin, primary, Wright, John, primary, Sullivan, Daniel M., primary, Roberts, John D., primary, and Grant, Steven, primary

Published
2023
Full Text
View/download PDF

21. Supplementary Methods and Table 1 from Phase I Study of Topotecan, Ifosfamide, and Etoposide (TIME) with Autologous Stem Cell Transplant in Refractory Cancer: Pharmacokinetic and Pharmacodynamic Correlates

Author

Perkins, Janelle B., primary, Goldstein, Steven C., primary, Dawson, Jana L., primary, Kim, Jongphil, primary, Field, Teresa L., primary, Partyka, James S., primary, Fields, Karen K., primary, Maddox, Beth L., primary, Simonelli, Christine E., primary, Neuger, Anthony M., primary, Lush, Richard M., primary, and Sullivan, Daniel M., primary

Published
2023
Full Text
View/download PDF

22. Supplementary Data from Interrogating Two Schedules of the AKT Inhibitor MK-2206 in Patients with Advanced Solid Tumors Incorporating Novel Pharmacodynamic and Functional Imaging Biomarkers

Author

Yap, Timothy A., primary, Yan, Li, primary, Patnaik, Amita, primary, Tunariu, Nina, primary, Biondo, Andrea, primary, Fearen, Ivy, primary, Papadopoulos, Kyriakos P., primary, Olmos, David, primary, Baird, Richard, primary, Delgado, Liliana, primary, Tetteh, Ernestina, primary, Beckman, Robert A., primary, Lupinacci, Lisa, primary, Riisnaes, Ruth, primary, Decordova, Shaun, primary, Heaton, Simon P., primary, Swales, Karen, primary, deSouza, Nandita M., primary, Leach, Martin O., primary, Garrett, Michelle D., primary, Sullivan, Daniel M., primary, de Bono, Johann S., primary, and Tolcher, Anthony W., primary

Published
2023
Full Text
View/download PDF

23. Supplementary Data from Novel 5′ Untranslated Region Variants of BCRP mRNA Are Differentially Expressed in Drug-Selected Cancer Cells and in Normal Human Tissues: Implications for Drug Resistance, Tissue-Specific Expression, and Alternative Promoter Usage

Author

Nakanishi, Takeo, primary, Bailey-Dell, Kimberly J., primary, Hassel, Bret A., primary, Shiozawa, Ken, primary, Sullivan, Daniel M., primary, Turner, Joel, primary, and Ross, Douglas D., primary

Published
2023
Full Text
View/download PDF

24. Supplementary Table S1 from Novel 5′ Untranslated Region Variants of BCRP mRNA Are Differentially Expressed in Drug-Selected Cancer Cells and in Normal Human Tissues: Implications for Drug Resistance, Tissue-Specific Expression, and Alternative Promoter Usage

Author

Nakanishi, Takeo, primary, Bailey-Dell, Kimberly J., primary, Hassel, Bret A., primary, Shiozawa, Ken, primary, Sullivan, Daniel M., primary, Turner, Joel, primary, and Ross, Douglas D., primary

Published
2023
Full Text
View/download PDF

31. Spending and Job Search Impacts of Expanded Unemployment Benefits: Evidence from Administrative Micro Data

Author

Ganong, Peter, Greig, Fiona, Liebeskind, Max, Noel, Pascal, Sullivan, Daniel M., and Vavra, Joseph

Subjects
economics
Abstract

How did the largest expansion of unemployment benefits in U.S. history affect household behavior? Using anonymized bank account data covering millions of households, we provide new empirical evidence on the spending and job search responses to benefit changes during the pandemic and compare those responses to the predictions of benchmark structural models. We find that spending responds more than predicted, while job search responds an order of magnitude less than predicted. In sharp contrast to normal times when spending falls after job loss, we show that when expanded benefits are available, spending of the unemployed actually rises after job loss. Using quasi-experimental research designs, we estimate a large marginal propensity to consume out of benefits. Notably, spending responses are large even for households who have built up substantial liquidity through prior receipt of expanded benefits. These large responses contrast with a theoretical prediction that spending responses should shrink with liquidity. Simple job search models predict a sharp decline in search in the wake of a substantial benefit expansion, followed by a sustained rebound when benefits expire. We instead find that the job-finding rate is quite stable. Moreover, we document that recall plays an important role in driving job-finding dynamics throughout the pandemic. A model extended to fit these key features of the data implies small job search distortions from expanded unemployment benefits. Jointly, these spending and job finding facts suggest that benefit expansions during the pandemic were a more effective policy than predicted by standard structural models. Abstracting from general equilibrium effects, we find that overall spending was 2.0-2.6 percent higher and employment only 0.2-0.4 percent lower as a result of the benefit expansions.

Published
2022
Full Text
View/download PDF

45. FDG-PET Lymphoma Demonstration Project Invitational Workshop

Author

Kelloff, Gary J., Sullivan, Daniel M., Wilson, Wyndham, Cheson, Bruce, Juweid, Malik, Mills, George Q., Zelenetz, Andrew D., Horning, Sandra J., Weber, Wolfgang, Sargent, Daniel J., Dodd, Lori, Korn, Edward, Armitage, James, Schilsky, Richard, Christian, Michaele, O’Connor, Owen A., Wang, Sue Jane, Farrell, Ann T., Pazdur, Richard, Graham, Michael, Wahl, Richard L., Larson, Steven M., Kostakoglu, Lale, Daube-Witherspoon, Margaret, Gastonis, Constantine, Siegel, Barry A., Shankar, Lalitha K., Lee, David B., Higley, Howard R., Sigman, Caroline C., Carucci, Daniel, Timko, David, deGennaro, Louis J., Sigal, Ellen, Barker, Anna, and Woodcock, Janet

Published
2007
Full Text
View/download PDF

47. Measurement of multisite oxidation kinetics reveals an active site conformational change in Spo0F as a result of protein oxidation

Author

Sharp, Joshua S., Sullivan, Daniel M., Cavanagh, John, and Tomer, Kenneth B.

Subjects
Oxidation-reduction reaction -- Research, Bacillus subtilis -- Research, Proteins -- Chemical properties, Conformational analysis, Biological sciences, Chemistry
Abstract

Oxidative surface mapping is used through mass spectrometry to independently and simultaneously monitor the solvent accessibility of more than 13 different oxidation targets in the sporulation-inducing protein Spo0F in Bacillus subtilis. By measuring deviations in the rate of oxidation from the expected pseudo-zero-order kinetics, local structural changes due to the oxidative damage is detected and characterized.

Published
2006

49. Implementation of Timeline Reforms Speeds Initiation of National Cancer Institute–Sponsored Trials

Author

Abrams, Jeffrey S., Mooney, Margaret M., Zwiebel, James A., Korn, Edward L., Friedman, Steven H., Finnigan, Shanda R., Schettino, Patricia R., Denicoff, Andrea M., Kruhm, Martha G., Montello, Mike, Misra, R. Rita, Ansher, Sherry S., DiPiazza, Kate J., Souhan, Erin M., Wickerham, D. Lawrence, Giantonio, Bruce J., O’Donnell, Robert T., Sullivan, Daniel M., Soto, Nancy I., Fleming, Gini F., Prindiville, Sheila A., Petryshyn, Ray A., Hautala, Judith A., Grad, Oren, Zuckerman, Brian L., Meyer, Ralph M., Yao, James C., Baker, Laurence A., Buckner, Jan C., Hortobagyi, Gabriel N., and Doroshow, James H.

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results